Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients ≥65.

Roberto Bordonaro(Ospedale Garibaldi), David Ferry(Eli Lilly (United States)), Emmanuelle Dochy(Sanofi (Belgium)), Chiara Zilocchi(Sanofi (Italy)), Anne Thomas(Leicester Royal Infirmary), Giovanni Luca Frassineti, Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Alberto F. Sobrero(Ospedale Policlinico San Martino), Yan Moore(Sanofi (United States)), Libero Ciuffreda(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Julien Taı̈eb(Hôpital Européen Georges-Pompidou)
Journal of Clinical Oncology
January 20, 2014
10.1200/jco.2014.32.3_suppl.545
Cited by 8

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|728
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701